Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome

Urol Clin North Am. 2017 Nov;44(4):575-585. doi: 10.1016/j.ucl.2017.07.006.

Abstract

Prostate cancer lesions smaller than 0.5 m3, or Gleason pattern 3, are likely clinically insignificant. Clinically significant disease is often limited to a single index lesion. Focal ablation targets this index lesion, maintains oncological control, and minimizes complications by preserving healthy prostate tissue. Template mapping biopsy or multiparametric MRI-targeted biopsies are used to identify appropriate index lesions. Multiple energy modalities have been tested, including high-intensity frequency ultrasound, cryoablation, laser ablation, photodynamic therapy, focal brachytherapy, radiofrequency ablation, irreversible electroporation. Outcome is assessed by biopsy of the target area, triggered by prostate-specific antigen measurements or MRI imaging, or performed per protocol at 12 months.

Keywords: Cryotherapy; High-intensity focused ultrasound ablation; Laser therapy; Photodynamic therapy; Prostate cancer.

Publication types

  • Review

MeSH terms

  • Ablation Techniques / methods*
  • Biopsy
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Neoplasm Grading*
  • Patient Selection*
  • Practice Guidelines as Topic*
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / surgery*
  • Treatment Outcome